ONOlga A. Neprelyuk

Olga A. Neprelyuk

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Olga A. Neprelyuk has a total of 10 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Molecular Signaling and Biased Agonism of the CHEMR23 Receptor: Implications for Inflammation Resolution and Bone Remodeling

    by Olga A. Neprelyuk, Inessa G. Romanenko, Oksana L. Irza, Maxim A. Kriventsov, Sergei Ya Neprelyuk

    The chemerin chemokine-like receptor 1 (CHEMR23), a member of the G proteincoupled receptor (GPCR) family, has emerged as a key regulator of immune homeostasis and skeletal remodeling. Notably, CHEMR23 exhibits ligand-specific biased agonism, enabling divergent intracellular signaling pathways depending on the ligand involved. Pro-inflammatory ligands such as chemerin predominantly activate Gi/o protein–dependent cascades, promoting cytokine release, osteoclastogenesis, and tissue degradation. In contrast, the binding of specialized proresolving mediators (SPMs), such as resolvins, preferentially triggers β-arrestin–mediated signaling. This pathway suppresses NF-κB activation, promotes macrophage polarization toward a proresolving phenotype, and facilitates the resolution of inflammation. This signaling bifurcation is particularly relevant in chronic inflammatory diseases characterized by progressive bone loss, including periodontitis. Expression of CHEMR23 is dynamically modulated by inflammatory stimuli, metabolic stress, and genetic polymorphisms, underscoring its potential as a target for resolution- directed therapies. Emerging therapeutic strategies, ranging from lipid-derived SPMs to monoclonal antibodies, are under investigation for their ability to modulate CHEMR23 activity in a ligand- and context-specific manner. This review provides an integrated overview of molecular, cellular, and translational data on CHEMR23, emphasizing its dual functional roles and therapeutic potential in inflammation-associated pathologies.


  • Open Access

    The impact of omega-3 fatty acids in a combined experimental model of periodontitis and metabolic syndrome

    by O. A. Neprelyuk, S. I. Zhad'KO, I. G. Romanenko, A. Ya. Neprelyuk, M. A. Kriventsov, А. Я. Непрелюк

    Relevance. Periodontitis and metabolic syndrome are interrelated conditions that often aggravate each other through shared pathogenic mechanisms, highlighting the need for integrated immunomodulatory therapeutic approaches. Despite this, existing literature presents inconsistent data regarding the interplay between periodontitis and metabolic syndrome, as well as limited insights into the potential benefits of omega-3 polyunsaturated fatty acids (ω-3 PUFAs) as an adjuvant therapy. Specifically, the role of ω-3 PUFAs in modulating the inflammatory response and mitigating bone resorption remains inadequately explored. Therefore, this study aims to evaluate the inflammatory response and osteoresorption in periodontal tissues under the combined conditions of periodontitis and metabolic syndrome, while also assessing the therapeutic effects of ω-3 PUFAs.Materials and methods. This experimental study was conducted using 30 male Wistar rats, which were randomly assigned to one of five groups: a control group, a periodontitis group, a combined periodontitis and metabolic syndrome group, a periodontitis group treated with omega-3 fatty acids, and a combined periodontitis and metabolic syndrome group treated with omega-3 fatty acids. The study employed several research methodologies. Biochemical analyses were performed to confirm the presence of metabolic syndrome. Histopathological and morphometric assessments were conducted to evaluate the inflammatory response, the extent of osteoresorption, and the number of osteoclasts in the periodontal tissues. Additionally, molecular genetic analysis was used to measure the relative mRNA expression levels of key inflammatory and osteoclastogenic markers, including TNFα, IL-1β, RANK, and OPG.Results. The data demonstrated that metabolic syndrome in laboratory animals significantly exacerbates both the pro-inflammatory response and the extent of lacunar osteoclastic bone resorption. Administration of ω-3 PUFAs at a dose of 40 mg/kg over 30 days led to a statistically significant reduction in inflammatory infiltration within the periodontal tissues (3.17 ± 0.21 in the control group vs. 1.83 ± 0.21 in the treated group, р = 0.001) and a decrease in the number of osteoclasts (3,75 ± 0,45 in the control group vs. 1,75 ± 0,35 in the treated group, р = 0.003). Additionally, there was a notable reduction in the expression levels of TNFα, IL-1β, and RANK mRNA. Similar but less pronounced effects were observed in the group with combined metabolic syndrome following ω-3 PUFA administration.Conclusion. These findings enhance the current understanding of the interplay between periodontitis and metabolic syndrome, highlighting the potential of ω-3 PUFAs as a preventive or therapeutic intervention. ω-3 PUFAs may be effective in mitigating inflammatory responses and bone resorption, both in cases of isolated periodontitis and when accompanied by metabolic syndrome.

  • Open Access

    Resolution phase of inflammation, resolvins and periodontitis: review

    by О.а. Непрелюк, С.и. Жадько, О.л. Ирза, М.а. Кривенцов

    Представлены данные, касающиеся современных представлений о разрешающей фазе воспаления и роли резолвинов в качестве нового класса эндогенных веществ — производных омега-3-полиненасыщенных жирных кислот (эйкозапентаеновой и докозагексаеновой), применительно к хроническому воспалению тканей пародонта. Основываясь на первоначальных исследованиях резолвинов, а также на данных исследований in vitro и in vivo в экспериментальных моделях пародонтита, в систематизированном виде представлены данные в отношении ключевых биологических эффектов резолвинов, а также их влияния на течение воспалительного ответа и резорбцию костной ткани альвеолярного отростка челюсти. С учетом выявленных эффектов и основных патогенетических механизмов, вовлеченных в развитие пародонтита, систематизированы данные в отношении потенциальных ключевых точек приложения резолвинов на течение пародонтита, а также обозначены перспективные направления дальнейших исследований. The literature review presents data on modern ideas about the resolving phase of inflammation and the role of resolvins as a new class of endogenous substances — derivatives of omega-3 polyunsaturated fatty acids (eicosapentaenoic acid and docosahexaenoic acid), in relation to chronic inflammation of periodontal tissues. Based on initial studies of resolvins, as well as data from in vitro and in vivo studies in experimental models of periodontitis, data are presented in a systematic way regarding the key biological effects of resolvins, as well as their impact on the course of the inflammatory response and bone resorption of the alveolar process of the jaw. Taking into account the identified effects and the main pathogenetic mechanisms involved in the development of periodontitis, data on potential key points of application of resolvins on the course of periodontitis are systematized, as well as promising areas for further research are identified.


  • Open Access

    Immunohistochemical profile of gingiva biopsy samples from the edentulous alveolar ridge in the jaw

    by A. S. Kulikov, S. I. Zhad’kO, I. G. Romanenko, O. A. Neprelyuk, T. P. Makalish, M. A. Kriventsov

    Relevance. Despite the high success rate of dental implantation in restoring anatomical occlusion and achieving desired aesthetic effects, complications, often mediated by peri-implantitis, remain an area requiring further study. This study aimed to morphologically assess gingiva biopsy samples from the edentulous alveolar ridge of the jaw, using immunohistochemical markers for immunophenotyping different subpopulations of inflammatory cells, inter alia.Material and methods. Gingiva biopsy specimens from 25 patients underwent descriptive histological and immunohistochemical analyses, employing markers such as CD3, CD20, TBX21, GATA3, Foxp3, CD68, CD80, CD163, CD1a, and CD83. The study includes clinical-anamnestic data analysis, descriptive histological and immunohistochemical observations, and a quantitative analysis of the abundance of various immunopositive cell subpopulations.Results. The data indicated that approximately one third of the gum tissues exhibited signs of a chronic inflammatory response, predominantly characterized by the primary T-cell subpopulation of T-helper 1 cells, a minimal presence of regulatory T-cells, and an almost complete absence of T-helper 2 cells. Additionally, an inflammatory cell mix was observed, comprising a significant proportion of B-cells, monocyte-macrophage cells (mainly M2 macrophage subpopulation), and mature CD83+ dendritic cells. These changes reflect a pro-inflammatory local immune response, crucial to consider in future implantation planning.Conclusion. The analysis of this pilot clinical case series enhances our understanding of the gingiva condition in the edentulous alveolar ridge before dental implantation and opens avenues for further research in this field.

  • Adjunctive use of omega‐3 fatty acids in combination with low‐dose aspirin in periodontitis: Systematic review and meta‐analysis

    by Olga A. Neprelyuk, Sergey I. Zhad'KO, Inessa G. Romanenko, Maxim A. Kriventsov

    Periodontitis is one of the most common dental diseases with a range of treatment approaches, including pathogenetically reasonable use of various host immune modulators. One such approach is the use of omega‐3 polyunsaturated fatty acids (PUFAs) in combination with low‐dose aspirin. This systematic review and meta‐analysis were performed to compare the standard treatment alone and adjunctive use of omega‐3 PUFAs in combination with low‐dose aspirin with or without standard treatment in patients with periodontitis. A systematic review of the literature was performed using MEDLINE/PubMed, Cochrane Central and Google Scholar databases. Selection criteria included the following: randomized controlled trials in subjects with periodontitis in the age group above 18 years old, with follow‐up periods ranging from 6 weeks to 6 months. The meta‐analysis was performed using standard methodological procedures according to Cochrane recommendations, including assessment of risk‐of‐bias and level of evidence (GRADE). Meta‐analysis was performed for such clinical outcomes as plaque index (PI), gingival index (GI), probing depth (PD), clinical attachment loss (CAL), bleeding on probing (BOP) and bleeding index (BI) based on data from seven randomized clinical trials conducted between 2010 and 2020. It was shown that adjunctive use of omega‐3 PUFAs in combination with low‐dose aspirin results in significant clinical improvement in PD, CAL and GI during both short and prolonged follow‐up periods. The use of omega‐3 PUFAs and low‐dose aspirin in periodontitis patients may be promising as an adjunct therapy, however, due to a limited number of patients and significant heterogeneity, further studies need to be conducted.